About BioCardia

We are a clinical-stage regenerative medicine company.

Our Mission: To bring to market comprehensive cell therapy solutions for the treatment of cardiovascular diseases with large unmet medical needs.

Our Pipeline: Our lead therapeutic candidate is the investigational CardiAMP™ Cell Therapy System, which provides an autologous bone marrow derived cell therapy (using a patient's own cells) for the treatment of two clinical indications - heart failure that develops after a heart attack and chronic myocardial ischemia.

The Company’s second therapeutic platform, the CardiALLO™  Cell Therapy System, is an investigational culture expanded bone marrow derived allogenic or “off the shelf” cell therapy using neurokinin-1 receptor positive mesenchymal stem cells for the treatment of cardiac and pulmonary disease.



News

04 Mar

Henry Ford Health System

Henry Ford Health System Studies Novel Cell Therapy Aimed at Improving Heart Failure Symptoms
Read More
08 Feb

Cell & Gene

Inside BioCardia's CardiAMP Cell Therapy
Read More
15 Sep

BioTuesdays

BioCardia developing autologous and allogenic cardiovascular cell therapies
Read More
03 Aug

Pharmaceutical Technology

BioCardia’s novel CardiAMP stem cell therapy closer to approval in heart failure
Read More
28 Jul

The Big Biz show

The Big Biz Show interviews BioCardia CEO, Peter Altman
Read More
10 Jan

HealthCare Weekly

5 Innovations That Will Change the Treatment of Heart Disease
Read More

press releases

10 Sep
2021 CardiAMP Cell Therapy Heart Failure Trial to be Featured in Two Presentations at Heart Failure Society of America Annual Meeting 2021
09 Sep
2021 BioCardia Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (Virtual Conference)
13 Aug
2021 BioCardia to Participate in Upcoming Investor Conferences
12 Aug
2021 BioCardia Reports Second Quarter 2021 Financial Results and Business Highlights
04 Aug
2021 BioCardia to Participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference on August 10, 2021
15 Jul
2021 BioCardia Announces Japanese Patent on Imaging System for Targeting Cardiac Therapies
Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS